Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328095 | Acta Haematologica Polonica | 2014 | 9 Pages |
Abstract
High-risk myelodysplastic syndromes (MDS) are defined by patients who fall into Intermediate-2 or High-risk group categories in the International Prognostic Scoring System or High/Very high in the revised IPSS (R-IPSS). High-risk MDS carry a major risk of progression to acute myeloid leukemia and short survival. Standard therapies include allogeneic stem cell transplantation, induction therapy (AML-like) and hypomethylating agents. This article presents recent European LeukemiaNet recommendations for treatment of high-risk MDS.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Agnieszka Wierzbowska, Agnieszka Pluta,